This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
BELLUS Health Inc.
Drug Names(s): ShigamAbs, cαStx1 and cαStx2 combination
Description: ShigamAbs is a chimeric anti-Shiga toxin antibody consisting of two monoclonal antibodies that bind specifically to Shiga toxins 1 and 2. The antibodies are caStx1 and caStx2, which are combined for a single dose treatment.
Shigatoxin-producing E. coli (STEC) is primarily a foodborne bacterial infection affecting approximately 314,000 people annually in the industrialized world. Most STEC secrete two toxins, Shigatoxin 1 (Stx1) and Shigatoxin 2 (Stx2) which can cause serious health complications, particularly in young children and the elderly. STEC infection is characterized by acute diarrhoea with severe abdominal cramps. Bloody diarrhoea is observed in about 70% of all STEC cases. In 10-15% of STEC cases patients progress to Hemolytic Uremic Syndrome (HUS) a life-threatening condition that results in a combination of red blood cell destruction, acute renal failure and a low platelet count. HUS is the most important cause of acute renal failure in children which can lead to end-stage renal disease requiring dialysis and possibly kidney transplantation.
Deal Structure: Shigamabs were originally developed by Thallion Pharmaceuticals.
Thallion and LFB Group
In December 2009, Thallion and LFB Group entered an partnership for development and commercialization of Shigamabs. Under the terms of a definitive agreement, LFB Biotechnologies will receive commercial rights to Shigamabs for Europe and South America, while Thallion retains the rights for North America and the rest of world. Thallion can receive payments of up to $95 million (approximately C$150 million), which includes an up-front licensing fee of $1.5 million (approximately C$2.3 million), funding for substantially all future clinical development costs, as well as milestone payments associated with the development, approval and commercial sales of Shigamabs. In addition, Thallion will receive tiered, double digit royalties based on product sales. Thallion will retain primary responsibility for the conduct of the clinical program, whereas LFB Biotechnologies will be responsible for...See full deal structure in Biomedtracker
Additional information available to subscribers only: